Independent comparison · May 2026
Quick answer
Wegovy and Ozempic contain the same active ingredient — semaglutide. The differences are dose (Wegovy reaches higher therapeutic doses), FDA approval (Wegovy for chronic weight management, Ozempic for type 2 diabetes), and price (Wegovy lists slightly higher). Insurance treats them very differently because of the indication on the prescription.
| Attribute | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-approved for | Chronic weight management | Type 2 diabetes |
| Max dose | 2.4 mg weekly | 2.0 mg weekly |
| List price | ~$1,349/month | ~$968/month |
| Insurance coverage for weight loss | Sometimes | Rarely (off-label) |
| Direct cash-pay program | $349/month | Limited |
FDA approval is indication-specific. Novo Nordisk submitted semaglutide first as a diabetes drug (Ozempic, approved 2017) and later as a weight-management drug (Wegovy, approved 2021). Same molecule, different label, different dose ceiling, different insurance treatment.
Insurance plans usually require an FDA-approved indication for coverage. Wegovy is approved for weight management; Ozempic prescribed off-label for weight loss is generally not covered.
Wegovy was studied at 2.4 mg in the STEP 1 trial — average 14.9% body-weight loss at 68 weeks. Ozempic's diabetes-trial doses topped out at 2.0 mg, which produces a smaller weight-loss effect.
If someone is using Ozempic off-label for weight loss, the effect is meaningful but typically lower than Wegovy at full titration — closer to 8–11% average body-weight loss.
Wegovy now has a direct cash-pay program at $349/month through the manufacturer. Ozempic prices remain near retail because most patients are using insurance through a diabetes diagnosis.
Compounded semaglutide via telehealth is materially cheaper than either — starting around $99/month — and contains the same active ingredient at a provider-determined dose.
Independently rated providers that prescribe these medications, sorted by editorial score.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
They contain the same active ingredient, semaglutide, and are made by the same manufacturer. Wegovy is FDA-approved for chronic weight management at higher doses (up to 2.4 mg); Ozempic is approved for type 2 diabetes at lower doses (up to 2.0 mg).
It is prescribed off-label by some clinicians but insurance rarely covers Ozempic for non-diabetic patients. The FDA-approved path for weight loss is Wegovy, with compounded semaglutide through telehealth providers as a lower-cost alternative.
Higher therapeutic dose (more milligrams of active ingredient per pen), positioning as a weight-management drug, and a different reimbursement model. Manufacturer cash-pay programs in 2026 have closed the gap somewhat, with Wegovy at $349/month direct.